Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $940.00 by Analysts at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective trimmed by Truist Financial from $975.00 to $940.00 in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts also recently issued reports on the company. Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. TD Cowen cut their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $912.20.

Regeneron Pharmaceuticals Stock Up 5.2 %

REGN stock opened at $598.76 on Wednesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $631.31 and its 200 day moving average price is $717.21. Regeneron Pharmaceuticals has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a market cap of $65.46 billion, a P/E ratio of 15.64, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. During the same period last year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals’s revenue was down 3.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in REGN. Virtu Financial LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $6,364,000. Morse Asset Management Inc boosted its holdings in Regeneron Pharmaceuticals by 0.9% in the third quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock valued at $5,053,000 after purchasing an additional 43 shares during the last quarter. Anchor Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 212.0% during the 3rd quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 583 shares in the last quarter. Sculati Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock worth $1,970,000 after purchasing an additional 38 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co increased its holdings in Regeneron Pharmaceuticals by 19.0% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock worth $5,575,000 after purchasing an additional 848 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.